Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center, discusses the current standard of treatment for patients with advanced endometrial cancer as well as the role novel therapies, such as targeted therapies and immunotherapy, play in the treatment of the disease.
Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center, discusses the current standard of treatment for patients with advanced endometrial cancer as well as the role novel therapies, such as targeted therapies and immunotherapy, play in the treatment of the disease.
Transcript
What is the current standard of treatment for patients with advanced endometrial cancer?
Our current standard of care treatment for advanced endometrial cancer would usually be surgery first, if it looks doable by their imaging, meaning it’s confined to the abdomen and pelvis, there’s not distant disease like in the lungs or someplace where we don’t think we can resect it. Then, usually that’s followed by chemotherapy. The 2 drugs that have the greatest efficacy for endometrial cancer right now is paclitaxel and carboplatin, and usually that’s 6 cycles of both treatments. Then, plus or minus radiation, depending on the treating gynecologic oncologist’s preference and sort of risk factors and things in where the cancer was and wasn’t during the surgery.
Do targeted therapies or immunotherapy play a role in the treatment of endometrial cancer? Are there any identified biomarkers to predict response to these therapies?
So, right now there haven’t been any FDA approved treatments for endometrial cancer, which would include targeted therapies, actually since hormonal therapy. So, we really desperately need more research on targeted therapies for endometrial cancer for sure. We are looking at many things, including mTOR inhibitors. We’re looking at antiangiogenic agents.
I think the things we’re most excited about is PD-1 inhibitor therapy with mismatched repair deficient tumors looking like a good biomarker for immunotherapy for endometrial cancer. Also, endometrial cancers have a fair amount of tumors that are mismatched repair deficient. So, I think right now that’s our most exciting biomarker and treatment, and there is FDA approval for PD-1 inhibitors in patients across cancers that have mismatched repair deficient tumors.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More